<DOC>
	<DOC>NCT03008109</DOC>
	<brief_summary>EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS （progression-free survival） , the OS （ overall survival） is limited extended. This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.</brief_summary>
	<brief_title>Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Advanced NSCLC,EGFR mutation positive,PS（performance status） 02,Patients were required to have one or more measurable lesions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR-TKI</keyword>
	<keyword>Recombinant human endostatin</keyword>
</DOC>